FOOD AND DRUG ADMINISTRATION

First Page		Document Content
Orphan drugs Amides Bortezomib Pyrazines Multiple myeloma Dexamethasone Panobinostat End point of clinical trials Plasma cell leukemia Chemistry Organic chemistry Medicine		FOOD AND DRUG ADMINISTRATION Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 20,97 KB Share Document on Facebook

	Anti-AML activity of combined epigenetic therapy with novel DNMT1 inhibitors SGI-110 and SGI1036 and histone deacetylase inhibitor panobinostat. Warren Fiskus1, Pace Johnston1, Rajeshree Joshi1, Rekha Rao1, Celalettin Us DocID: 10iIb - View Document
	OPEN Citation: Cell Death and Disease[removed], e798; doi:[removed]cddis[removed] & 2013 Macmillan Publishers Limited All rights reserved[removed]www.nature.com/cddis DocID: ZVJc - View Document
	Bauer et al Phase I panobinostat plus imatinib in GIST DocID: VYoR - View Document
	FARYDAK (panobinostat) histone deactylase inhibitor DocID: U2rk - View Document
	ASCO[removed]Clinical response by baseline characteristics in patients with relapsed and bortezomib-refractory multiple myeloma treated with panobinostat, bortezomib, and dexamethasone (PANORAMA 2) Melissa Alsina,1 Paul G. DocID: PQXx - View Document